Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Cancer Research Technology and AstraZeneca extend cancer metabolism alliance

March 11, 2013

Maximum tolerated dose defined in CH-5132799 study

March 8, 2013

Genentech presents phase I results for GDC-0068

March 8, 2013

Cylene and TetraGene enter exclusive worldwide agreement for anticancer candidate

March 8, 2013

Novogen signs memorandum of understanding with The Ingham Institute

March 8, 2013

Phase II study of palifosfamide in incurable germ cell tumors begins

March 8, 2013

Senesco takes steps to accelerate enrollment in phase Ib/IIa study of anticancer candidate

March 8, 2013

FDA approves use of two Dako assays with Genentech's new breast cancer medicine

March 7, 2013

Nymox provides update on U.S. phase II trial in early-stage prostate cancer

March 7, 2013

Clinical results reported for ATU-027 in patients with advanced solid tumors

March 7, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...